{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:27:06Z","timestamp":1790692026791,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Canadian Foundation for Innovation, Hamilton Health Sciences Organization"},{"name":"Janssen Canada and Pfizer Canada"},{"name":"speaker\u2019s bureau honoraria from Allergan"},{"name":"Lundbeck Canada"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Tilray"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.jpsychires.2019.01.024","type":"journal-article","created":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:21:57Z","timestamp":1548980517000},"page":"134-139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"special_numbering":"C","title":["Cannabis use behaviors and prevalence of anxiety and depressive symptoms in a cohort of Canadian medicinal cannabis users"],"prefix":"10.1016","volume":"111","author":[{"given":"Jasmine","family":"Turna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1948-3842","authenticated-orcid":false,"given":"Philippe","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Van Ameringen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychires.2019.01.024_bib1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00004850-199506000-00003","article-title":"Assessing the efficacy of treatments for panic disorder and agoraphobia: II. The Panic and Agoraphobia Scale","volume":"10","author":"Bandelow","year":"1995","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2019.01.024_bib2","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/npp.2011.6","article-title":"Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-na\u00efve social phobia patients","volume":"36","author":"Bergamaschi","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2019.01.024_bib3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/da.1055","article-title":"Mini-SPIN: a brief screening assessment for generalized social anxiety disorder","volume":"14","author":"Connor","year":"2001","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.jpsychires.2019.01.024_bib4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/0269881110379283","article-title":"Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report","volume":"25","author":"Crippa","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2019.01.024_bib5","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/sj.npp.1300496","article-title":"The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis","volume":"29","author":"D'Souza","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2019.01.024_bib6","first-page":"1","article-title":"Cannabinoids and terpenes as chemotaxonomic markers in cannabis","volume":"3","author":"Elzinga","year":"2015","journal-title":"Nat. Prod. Chem. Res."},{"key":"10.1016\/j.jpsychires.2019.01.024_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/j.1552-4604.1981.tb02617.x","article-title":"The efficacy and safety of nabilone (a synthetic cannabinoid) in the treatment of anxiety","volume":"21","author":"Fabre","year":"1981","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jpsychires.2019.01.024_bib8","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2105\/AJPH.2017.303818","article-title":"Lower-risk cannabis use guidelines: a comprehensive update of evidence and recommendations","volume":"107","author":"Fischer","year":"2017","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.jpsychires.2019.01.024_bib9","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archgenpsychiatry.2008.519","article-title":"Distinct effects of \u03949-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing","volume":"66","author":"Fusar-Poli","year":"2009","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.jpsychires.2019.01.024_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/j.1552-4604.1981.tb02618.x","article-title":"Single-dose study of nabilone in anxious volunteers","volume":"21","author":"Glass","year":"1981","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jpsychires.2019.01.024_bib11","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap) \u2013 a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J. Biomed. Inf."},{"key":"10.1016\/j.jpsychires.2019.01.024_bib12","series-title":"Medical Document Authorizing the Use of Cannabis for Medical Purposes under the Access to Cannabis for Medial Purposes Regulations","author":"Health Canada","year":"2017"},{"key":"10.1016\/j.jpsychires.2019.01.024_bib13","first-page":"943","article-title":"Nabilone, a cannabinol derivative, in the treatment of anxiety neurosis","volume":"29","author":"Ilaria","year":"1981","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"10.1016\/j.jpsychires.2019.01.024_bib14","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/0014-2999(74)90129-0","article-title":"Cannabidiol interferes with the effects of \u03949-tetrahydrocannabinol in man","volume":"28","author":"Karniol","year":"1974","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jpsychires.2019.01.024_bib15","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/1471-244X-14-S1-S1","article-title":"Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders","volume":"14","author":"Katzman","year":"2014","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jpsychires.2019.01.024_bib1a","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1177\/0706743716659417","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments","volume":"61","author":"Kennedy","year":"2016","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2019.01.024_bib16","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/mpr.1359","article-title":"Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States","volume":"21","author":"Kessler","year":"2012","journal-title":"Int. J. Methods Psychiatr. Res."},{"key":"10.1016\/j.jpsychires.2019.01.024_bib17","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ\u20109: validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J.Gen. Int. Med."},{"key":"10.1016\/j.jpsychires.2019.01.024_bib18","first-page":"S200","article-title":"696 Beneficial effect of an oral cannabionoiid in patients with IBS","volume":"13","author":"Lee","year":"2009","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.jpsychires.2019.01.024_bib19","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.addbeh.2016.05.015","article-title":"Comparing adults who use cannabis medically with those who use recreationally: results from a national sample","volume":"61","author":"Lin","year":"2016","journal-title":"Addict. Behav."},{"key":"10.1016\/j.jpsychires.2019.01.024_bib20","series-title":"The Health Effects of Cannabis and Cannabinoids: the Current State of Evidence and Recommendations for Research","first-page":"289","article-title":"Mental health","author":"National Academies of Sciences, Engineering, and Medicine","year":"2017"},{"key":"10.1016\/j.jpsychires.2019.01.024_bib21","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1177\/0269881117699616","article-title":"Substitution of medical cannabis for pharmaceutical agents for pain, anxiety, and sleep","volume":"31","author":"Piper","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2019.01.024_bib22","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. ISBN 3-900051-07-0 URL http:\/\/www\/R-project.org\/."},{"key":"10.1016\/j.jpsychires.2019.01.024_bib23","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1089\/can.2016.0007","article-title":"A cross-sectional survey of medical cannabis users: patterns of use and perceived efficacy","volume":"1","author":"Sexton","year":"2016","journal-title":"Cannabis Cannabinoid Res."},{"key":"10.1016\/j.jpsychires.2019.01.024_bib24","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: the GAD-7","volume":"166","author":"Spitzer","year":"2006","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.jpsychires.2019.01.024_bib25","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/da.22664","article-title":"Is cannabis treatment for anxiety, mood, and related disorders ready for prime time?","volume":"34","author":"Turna","year":"2017","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.jpsychires.2019.01.024_bib2a","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000377625","article-title":"Three-year course of cannabis dependence and prediction of persistence","volume":"21","author":"van der Pol","year":"2015","journal-title":"Eur. Addict. Res."},{"key":"10.1016\/j.jpsychires.2019.01.024_bib26","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.drugpo.2013.08.010","article-title":"Cannabis for therapeutic purposes: patient characteristics , access, and reasons for use","volume":"24","author":"Walsh","year":"2013","journal-title":"Int. J. Drug Pol."},{"key":"10.1016\/j.jpsychires.2019.01.024_bib27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cpr.2016.10.002","article-title":"Medical cannabis and mental health: a guided systematic review","volume":"28","author":"Walsh","year":"2017","journal-title":"Clin. Psychol. Rev."},{"key":"10.1016\/j.jpsychires.2019.01.024_bib28","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1001\/jama.2015.6358","article-title":"Cannabinoids for medical use: a systematic review and meta-analysis","volume":"313","author":"Whiting","year":"2015","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.jpsychires.2019.01.024_bib29","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/BF00432554","article-title":"Action of cannabidiol on the anxiety and other effects produced by \u0394 9-THC in normal subjects","volume":"76","author":"Zuardi","year":"1982","journal-title":"Psychopharmacology"}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395618304783?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395618304783?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T11:11:27Z","timestamp":1758366687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395618304783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":31,"alternative-id":["S0022395618304783"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2019.01.024","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cannabis use behaviors and prevalence of anxiety and depressive symptoms in a cohort of Canadian medicinal cannabis users","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2019.01.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}